BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1989645)

  • 1. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance.
    Rosenblum MG; Cheung L; Murray JL; Bartholomew R
    Cancer Commun; 1991 Jan; 3(1):21-7. PubMed ID: 1989645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
    Rosenblum MG; Murray JL; Cheung L; Rifkin R; Salmon S; Bartholomew R
    Mol Biother; 1991 Mar; 3(1):6-13. PubMed ID: 1906286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A; Cameron RB; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
    Gridley DS; Slater JM; Stickney DR
    J Biol Response Mod; 1989 Dec; 8(6):593-602. PubMed ID: 2513378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of lysosomal activity with sensitivity and resistance to tumor necrosis factor in murine L929 cells.
    Liddil JD; Dorr RT; Scuderi P
    Cancer Res; 1989 May; 49(10):2722-8. PubMed ID: 2713856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from tumor necrosis factor-mediated cytolysis by platelets.
    Philippe C; Philippe B; Fouqueray B; Perez J; Lebret M; Baud L
    Am J Pathol; 1993 Dec; 143(6):1713-23. PubMed ID: 8256858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor production by human monocytes is a regulated event: induction of TNF-alpha-mediated cellular cytotoxicity by endotoxin.
    Kornbluth RS; Edgington TS
    J Immunol; 1986 Oct; 137(8):2585-91. PubMed ID: 3760568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha induces changes in the phosphorylation, cellular localization, and oligomerization of human hsp27, a stress protein that confers cellular resistance to this cytokine.
    Mehlen P; Mehlen A; Guillet D; Preville X; Arrigo AP
    J Cell Biochem; 1995 Jun; 58(2):248-59. PubMed ID: 7673331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and further characterization of a non-tumor necrosis factor alpha or beta differentiation-inducing cytokine, P48.
    Leftwich JA; Hall RE
    Cancer Res; 1989 Aug; 49(16):4459-65. PubMed ID: 2663142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1067-75. PubMed ID: 9620065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma.
    Bregman MD; Meyskens FL
    J Biol Response Mod; 1988 Aug; 7(4):384-9. PubMed ID: 3139842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF.
    Ortaldo JR; Winkler-Pickett R; Morgan AC; Woodhouse C; Kantor R; Reynolds CW
    J Immunol; 1987 Nov; 139(9):3159-65. PubMed ID: 3668253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity.
    Ziegler-Heitbrock HW; Möller A; Linke RP; Haas JG; Rieber EP; Riethmüller G
    Cancer Res; 1986 Nov; 46(11):5947-52. PubMed ID: 3756932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
    Rosenblum MG; Cheung L; Mujoo K; Murray JL
    Cancer Immunol Immunother; 1995 May; 40(5):322-8. PubMed ID: 7600565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.